La Domenica Del Corriere - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
RIO -0.4% 82.95 $
BCC -0.79% 67.39 $
CMSD -1.14% 19.29 $
BTI 1.37% 61.89 $
RBGPF -0.49% 75.65 $
CMSC -1.14% 19.28 $
BCE 0.37% 21.43 $
NGG 0.82% 84.29 $
GSK 0.52% 50.45 $
RYCEF -2.22% 17.59 $
JRI -1.21% 11.29 $
AZN 0.04% 184.45 $
RELX 1.16% 40.51 $
VOD -0.78% 15.37 $
BP 0.87% 45.7 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

E.Marmano--LDdC